SRC and sarcoma: We focused on Src, Ras and PI3K pathways, for which pharmacologic inhibitors are currently in clinical development in sarcoma, and we assessed tumors from the 3 Affymetrix oligonucleotide U133A datasets (Japan, MSKCC and UK datasets) in our study.